Please login to the form below

Not currently logged in
Email:
Password:

NOAC

This page shows the latest NOAC news and features for those working in and with pharma, biotech and healthcare.

Bayer/J&J claim new FDA okay for clot drug Xarelto

Bayer/J&J claim new FDA okay for clot drug Xarelto

The new indication gives Xarelto a leg up over other drugs in the novel oral anticoagulant (NOAC) class, which include Pfizer/Bristol-Myers Squibb’s Eliquis (apixaban), Boehringer Ingelheim’s Pradaxa ... The new indication could go some way towards

Latest news

  • CHMP backs Lynparza in breast cancer, Dupixent in asthma CHMP backs Lynparza in breast cancer, Dupixent in asthma

    be the first reversal agent for novel oral anticoagulants (NOACs) that target factor Xa. ... So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    Outside oncology, BMS’ top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee. ... Bayer and Johnson &Johnson have abandoned a 7, 000-patient trial pitting their novel oral anticoagulant (NOAC) Xarelto against aspirin for ischaemic stroke

More from news
Approximately 11 fully matching, plus 22 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    The use of oral anticoagulants in patients with atrial fibrillation. NOAC reversal agents. ... PCM Scientific is always open to additional sources of funding support to expand the educational offerings of the NOAC education site.

  • Cogora

    PCM Scientific, Cogora’s CME division, developed NOAC Education as an independent educational initiative with a single, central goal: to support clinicians in providing optimal anticoagulation care for patients at risk

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics